Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, at Dana-Farber Cancer Institute (DFCI) in Boston, MA and Dr. Kenneth C, Anderson, Chief, Division of Hematologic Neoplasia at DFCI.

Dr. Richardson's clinical research focuses on studying novel therapies for multiple myeloma. He was the lead investigator of the SUMMIT and APEX clinical trials that led to the FDA approval of bortezomib (Velcade(R)) for the treatment of multiple myeloma. More recently, he served as clinical trials core chair of the Multiple Myeloma Research Consortium, completing 5 years of service in the role this year. Dr. Anderson serves as Chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee and chairs the scientific advisory board for the Multiple Myeloma Research Foundation. In addition to playing an integral role in the development and approval of bortezomib (Velcade(R)), Drs. Richardson and Anderson led both preclinical and early phase clinical trials for the immunomodulatory drug lenalidomide (Revlimid(R)), leading to its FDA approval in 2007.

Juergen Engel, Ph.D., President and CEO at AEterna Zentaris stated, "We are very excited with Keryx's initiation of this Phase 3 trial with perifosine, our lead oncology compound. Based on prior positive results, we believe that perifosine could become a novel oral combination treatment of great benefit to patients suffering from multiple myeloma."

About the Phase 3 Trial Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(R)) and dexamethasone in approximately 400 patients with relapsed or relapsed/refractory multiple myeloma. Patients will be randomized to bortezomib (Velcade(R)) at 1.3 mg/m2 days 1, 4, 8 and 11 every 21 days in combination with dexamethasone 20 mg on the day of and day after bortezomib (Velcade(R)) treatment, and either pe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... August 19, 2014 XenoTech announces ... and cost-effective metabolite production from bioactive small molecules. ... platform, the technology enables convenient and timely assessment ... to XenoTech’s Vice President of Commercial Operations, Christian ... assessing clinical risk can be measured directly by ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... in Wisconsin, educations effect on the state economy and ... were a few of the many topics covered yesterday ... , ,The panel first discussed the relation between the ... Wisconsin-Madison Chancellor John Wiley began by citing ...
... a lot of lively correspondence with Midwest technology job seekers, ... hanging onto their jobs by their fingernails. , ,They write ... their experiences with finding a job, getting promoted and managing ... write about really annoying things that their co-workers and supervisors ...
... child waits for Christmas. Today, PalmOne introduces the ... I buy?" conundrum. , ,I saw the new Treo six weeks ... (Yes, even I take a break from the schmoozing to sneak ... fell in love. This newest handheld communicator takes everything that ...
Cached Biology Technology:UW and business leaders outline need for educated workers 2UW and business leaders outline need for educated workers 3Midwest technology bosses should stop flaunting their wealth at work 2Midwest technology bosses should stop flaunting their wealth at work 3Midwest technology bosses should stop flaunting their wealth at work 4Christmas comes early with Treo 650 2Christmas comes early with Treo 650 3
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
(Date:8/20/2014)... rugs and plastic bags could one day be made ... petroleum, scientists are now reporting. The novel process they ... deal with its agricultural and plastic waste problems, appear ... Athanassiou, Ilker S. Bayer and colleagues at the Italian ... constantly growing. In 2012, its production reached 288 million ...
(Date:8/20/2014)... a colony of honeybees grows to about 4,000 members, ... cycle: the building of a special type of comb ... of experts from the Department of Neurobiology and Behaviour ... starts the reproductive cycle of honeybee colonies. The results ... Science of Nature . , Reproduction isn,t always ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2
... fruits and vegetables in ozone-enriched environments reduces spoilage explains ... Conference in Harrogate. Dr Ian Singleton explains how ozone ... as it leaves no residue on foods. It ... can be lost due to microbial spoilage. Dr Singleton ...
... The benefits of blueberry consumption have been demonstrated ... benefits derived from their high polyphenol content. Blueberries ... on everything from aging to metabolic syndrome. Recently, ... Denton, TX, examined whether blueberries could play a ...
... 2010 For years, scientists have thought of DNA as ... RNA transcription. Now, research led by scientists from the Florida ... also act to fine-tune the activity of certain proteins known ... it possible to design therapies that could activate specific genes ...
Cached Biology News:Ozone reduces fungal spoilage of fruits and vegetables 2Blueberries may inhibit development of fat cells 2Scripps Research scientists uncover new DNA role in modifying gene function 2Scripps Research scientists uncover new DNA role in modifying gene function 3